RNA-based therapies in inherited retinal diseases
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
Inherited retinal diseases (IRDs) are a genetically and phenotypically heterogeneous group of genetic eye disorders. There are more than 300 disease entities, and together this group of disorders affects millions of people globally and is a frequent cause of blindness or low-vision certification. However, each type is rare or ultra-rare. Characteristically, the impaired vision in IRDs is due to retinal photoreceptor dysfunction and loss resulting from mutation in a gene that codes for a retinal protein. Historically, IRDs have been considered incurable and individuals living with these blinding conditions could be offered only supportive care. However, the treatment landscape for IRDs is beginning to evolve. Progress is being made, driven by improvements in understanding of genotype–phenotype relationships, through advances in molecular genetic testing and retinal imaging. Alongside this expanding knowledge of IRDs, the current era of precision medicine is fueling a growth in targeted therapies. This has resulted in the first treatment for an IRD being approved. Several other therapies are currently in development in the IRD space, including RNA-based therapies, gene-based therapies (such as augmentation therapy and gene editing), cell therapy, visual prosthetics, and optogenetics. RNA-based therapies are a novel approach within precision medicine that have demonstrated success, particularly in rare diseases. Three antisense oligonucleotides (AONs) are currently in development for the treatment of specific IRD subtypes. These RNA-based therapies bring several key advantages in the setting of IRDs, and the potential to bring meaningful vision benefit to individuals living with inherited blinding disorders. This review will examine the increasing breadth and relevance of RNA-based therapies in clinical medicine, explore the key features that make AONs suitable for treating genetic eye diseases, and provide an overview of the three-leading investigational AONs in clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The multilayered complexity of ceRNA crosstalk and competition
Tay, Y., Rinn, J., & Pandolfi, P. P. (2014) · Nature · doi:10.1038/nature12986 · Cited by 3,910 · cited 1×
“25 Further understanding this ceRNA network may provide a base to identify potential therapeutic targets or new prognostic biomarkers.”
BackgroundThe Noncoding RNA Revolution—Trashing Old Rules to Forge New Ones
Cech, T. R., & Steitz, J. A. (2014) · Cell · doi:10.1016/j.cell.2014.03.008 · Cited by 2,524
Hamel, C. (2006) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-1-40 · Cited by 962
Crooke, S. T., Witztum, J. L., Bennett, C. F., & Baker, B. F. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.03.004 · Cited by 841
Leber congenital amaurosis: Genes, proteins and disease mechanisms
den Hollander, A. I., Roepman, R., Koenekoop, R. K., & Cremers, F. P. M. (2008) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2008.05.003 · Cited by 811 · cited 1×
“36,64,69 The most common disease-causing mutation in CEP290 -associated IRD is c.2991 + 1655A > G (also known as p.Cys998*).”
BackgroundLong-Term Effect of Gene Therapy on Leber’s Congenital Amaurosis
Bainbridge, J. W. B., Mehat, M. S., Sundaram, V., Robbie, S. J., Barker, S. E., Ripamonti, C., Georgiadis, A., Mowat, F. M., Beattie, S. G., Gardner, P. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414221 · Cited by 743 · cited 2×
“…(per eye); Long-term expression of nuclease Non-permanent; treatment can be discontinued 36,41 Long-term durability still being investigated 42–44 Naked, no vectors needed; can target diseases with large, affected genes 45 Require viral vectors for delivery; usually limited to diseases with…”
BackgroundSelf-citationA Randomized Trial of Vitamin A and Vitamin E Supplementation for Retinitis Pigmentosa
Berson, E. L. (1993) · Archives of Ophthalmology · doi:10.1001/archopht.1993.01090060049022 · Cited by 465
Maguire, A. M., Russell, S., Wellman, J. A., Chung, D. C., Yu, Z.-F., Tillman, A., Wittes, J., Pappas, J., Elci, O., Marshall, K. A., et al. (2019) · Ophthalmology · doi:10.1016/j.ophtha.2019.06.017 · Cited by 409 · cited 2×
“39,46,49,52,53,60 It must be noted that cata-racts occur with intravitreal treatments.”
BackgroundSelf-citationWorldwide carrier frequency and genetic prevalence of autosomal recessive inherited retinal diseases
Hanany, M., Rivolta, C., & Sharon, D. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1913179117 · Cited by 408
Cukras, C., Wiley, H. E., Jeffrey, B. G., Sen, H. N., Turriff, A., Zeng, Y., Vijayasarathy, C., Marangoni, D., Ziccardi, L., Kjellstrom, S., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.05.025 · Cited by 268 · cited 1×
“61 Individuals receiving subretinal voretigene neparvovec-rzyl require the retina to be > 100 microns thick at the posterior pole.”
Cited by
The concept of gene therapy for glaucoma: the dream that has not come true yet
Sulak, R., Liu, X., & Smedowski, A. (2024) · Neural Regeneration Research · doi:10.4103/1673-5374.375319 · Cited by 40
Simons, E. J., & Trapani, I. (2023) · Human Gene Therapy · doi:10.1089/hum.2023.126 · Cited by 14
“32 Those in the most advanced phases of development are AONs and depending on the disease targeted rely on different mechanisms of actions 33 (Fig.”
Siles, L., & Pomares, E. (2025) · Molecular Therapy Nucleic Acids · doi:10.1016/j.omtn.2025.102482 · Cited by 4
Metadata
- Authors
- Girach, A., Audo, I., Birch, D. G., Huckfeldt, R. M., Lam, B. L., Leroy, B. P., Michaelides, M., Russell, S. R., Sallum, J. M. F., Stingl, K., Tsang, S. H., & Yang, P.
- Venue
- Therapeutic Advances in Ophthalmology
- Publisher
- SAGE Publications
- Published
- 2022-01
- Volume
- 14
- Pages
- 25158414221134602-25158414221134602
- ISSN
- 2515-8414 (ISSN-L)
- OpenAlex
- W4309411718
- Cited by
- 36
- References
- 21
- FWCI
- 2.35
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: RNA-based therapies in inherited retinal diseases. https://app.cochat.ai/papers/10.1177/25158414221134602
- The paper
- Girach, A., Audo, I., Birch, D. G., Huckfeldt, R. M., Lam, B. L., Leroy, B. P., Michaelides, M., Russell, S. R., Sallum, J. M. F., Stingl, K., Tsang, S. H., & Yang, P. (2022). RNA-based therapies in inherited retinal diseases. Therapeutic Advances in Ophthalmology. https://doi.org/10.1177/25158414221134602
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.